Skip to main content

2020 Year in Review - Non–Small-Cell Lung Cancer

Study evaluated the benefits of afatinib in Asian and non-Asian patients who had not received EGFR-TKI therapy for their EGFR-mutant NSCLC. Read More ›

Patients with untreated advanced NSCLC with EGFR mutations achieved improved progression-free survival with treatment with gefitinib and carboplatin plus pemetrexed compared with gefitinib alone. Read More ›

Researchers report higher overall response rate, median duration of response, and median progression-free survival in treatment-naïve patients with a MET exon 14 skipping mutation compared with previously treated patients. Read More ›

Researchers reported improved overall survival in patients with nonsquamous non–small-cell lung cancer with EGFR mutations. Read More ›

Tarloxotinib treatment was well tolerated and sizeable percentages of patients in both study cohorts achieved either partial response or stable disease. Read More ›

Osimertinib shows promise as an adjuvant treatment for patients with stage IB to IIIA EGFR mutation–positive NSCLC. Read More ›


Improved progression-free survival and overall survival in patients who received upfront stereotactic radiotherapy and TKI treatment should prompt additional study. Read More ›

Previously untreated patients and those who had received prior intracranial radiotherapy responded to selpercatinib treatment. Read More ›

Treatment was well tolerated and also associated with delayed progression in previously treated patients with NSCLC and METAmp/Ex14Δ. Read More ›

Page 2 of 3